News-Medical.Net October 16, 2024
Dr. Chinta Sidharthan

As AI technology evolves rapidly, the FDA is tackling the challenge of balancing innovation with patient safety, shaping regulations that ensure AI tools remain effective throughout their entire lifecycle.

A Special Communication published in the Journal of the American Medical Association (JAMA) examined the regulation of artificial intelligence (AI) in healthcare by the United States (U.S.) Food and Drug Administration (FDA). It also explored AI’s potential in clinical research, development of medical products, and patient care while highlighting the key areas to address as regulations are adapted for some of AI’s distinctive challenges in biomedicine and healthcare.

Background

Advances in AI have immense potential for transforming biomedicine and healthcare. Expectations from AI often exceed those from previous medical technologies such...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Regulations, Safety, Technology
Related Articles:
Device industry scrambles as FDA job cuts cause delays
FDA approves first rapid-acting insulin biosimilar for diabetes
Device industry scrambles amid concern FDA layoffs will cause delays
First Insulin Aspart Biosimilar Receives FDA Approval
In FDA job cuts, experts see threat of far-reaching impact

Share This Article